分化型甲状腺癌131I治疗对患者肝肾功能的影响

目的 研究应用放射性碘(131Ⅰ)治疗分化型甲状腺癌(DTC)对患者肝肾功能的影响.方法 收集接受131Ⅰ治疗的106例DTC患者的临床资料,并根据131Ⅰ治疗剂量分为低剂量组(≤1.85 GBq,n=19)、中剂量组(2.22 GBq和2.96 GBq,n=50)和高剂量组(≥3.7 GBq,n=37).对实施131Ⅰ治疗前后及各组患者的肝肾功能检查结果 进行对比分析.结果 接受131Ⅰ治疗前后,67例患者肝功能检查结果 记录完整(低剂量组18例,中剂量组37例,高剂量组12例).与治疗前比较,治疗后总体血清谷草转氨酶(AST)和谷丙转氨酶(ALT)水平升高(P<0.05),但大部分(82.1%)仍在正常范围内.接受131Ⅰ治疗前后,106例患者均具有完整的肾功能检查结果 记录.组内治疗前后患者血尿素氮(BUN)、肌酐(SCr)、尿酸(UA)水平比较,差异均无统计学意义(P>0.05).结论 131Ⅰ治疗DTC对患者肝肾功能无明显影响,是较为安全的治疗方法 .

Effects of 131I therapy for differentiated thyroid carcinoma on liver and renal function

Objective To investigate the effects of radioactive iodine (131I) therapy for differentiated thyroid carcinoma (DTC) on liver and renal function. Methods The clinical data of 106 patients with DTC were collected, and patients were divided into low dose group (≤1.85 GBq, n=19), middle dose group (2.22 GBq and 2.96 GBq, n=50) and high dose group (≥3.7 GBq, n=37) according to 131I doses. The results of liver and renal examinations were compared and analysed before and after 131I therapy among groups. Results The data of liver function were complete in 67 patients before and after 131I therapy (low dose group, n=18; middle dose group, n=37; high dose group, n=12). Compared with those before treatment, the total aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher (P<0.05), while the AST and ALT levels of the majority (82.1%) were in the normal ranges. The data of renal function were complete in all the 106 patients before and after 131I therapy. There was no significant difference in blood urea nitrogen (BUN), serum creatinine (SCr) and uric acid (UA) before and after treatment in each group (P>0.05). Conclusion 131I therapy is safe for DTC, with no significant effect on liver and renal function.